INFORMATION BY CANCER TYPE

Leukemia

A New Drug Is in the Pipeline for AML
BY Angelica Welch
Eunice Wang, M.D., discusses a promising new drug for the treatment of certain patients with acute myeloid leukemia.
Besponsa Gains FDA Approval to Treat Acute Lymphoblastic Leukemia
Besponsa (inotuzumab ozogamicin) was granted FDA approval for certain patients with ALL. 
Using 3D Animation to Prevent Chemotherapy Mistakes
BY Brielle Urciuoli
Driven by personal experience and his love for art, Ryan Berardi created a 3D animation that would help health care professionals if they wrongly administer chemotherapy to patients.
FDA Approves Vyxeos for Two Leukemia Types
BY Silas Inman
Vyxeos (CPX-351) was granted FDA approval for two subtypes of acute myeloid leukemia. 
Idhifa Approved by the FDA to Treat Relapsed AML
BY Silas Inman
Idhifa (enasidenib) was granted approval by the Food and Drug Administration (FDA) today, for the treatment of patients who have relapsed or refractory IDH2-mutated acute myeloid leukemia (AML).
Parent Age May Affect Child's Cancer Risk, Study Finds
BY Brielle Urciuoli
A recent study found that children of older parents may have an increased risk of certain types of cancers. 
Blincyto Granted FDA Approval for Leukemia Subset
BY Silas Inman
Blincyto (blinatumomab) was granted full approval by the Food and Drug Administration (FDA) to treat both children and adults with relapsed/refractory B-cell precursor acute lymphoblastic leukemia (ALL), regardless of Philadelphia chromosome (Ph) status, according to the developer of the anti-CD19 immunotherapy, Amgen.
Sprycel Granted Priority Review for Pediatric CML
BY Jason Harris
Children with Philadelphia chromosome-positive chronic phase chronic myeloid leukemia (CP Ph+ CML) may soon have a new treatment 
When Cancer Makes a Hospital a Home
BY Paul Pavao
My wife and I are always amazed at the fond memories and warm feelings that rise up when we return to Nashville.
FDA Approves Tool for Blood Cancer Detection
BY Silas Inman
ClearLLab multicolor reagents (T1, T2, B1, B2, M) gained approval from the Food and Drug Administration (FDA) to detect chronic leukemia, acute leukemia, non-Hodgkin lymphoma, multiple myeloma, myelodysplastic syndrome (MDS) and myeloproliferative neoplasms (MPN). This is the first approval the agency received for immunophenotyping on a flow cytometer.
 
Special Feature
Share Your Art
Talk about this article with other patients, caregivers, and advocates in the Leukemia CURE discussion group.
Search Cancer Drugs & Terms
Treatment
Information about treatment, including surgery, chemotherapy, radiation therapy, immunotherapy, and vaccine therapy
Adult Acute Lymphoblastic Leukemia Treatment (PDQ®)
Expert-reviewed information summary about the treatment of adult acute lymphoblastic leukemia.
Adult Acute Myeloid Leukemia Treatment (PDQ®)
Expert-reviewed information summary about the treatment of adult acute myeloid leukemia.
Childhood Acute Lymphoblastic Leukemia Treatment (PDQ®)
Expert-reviewed information summary about the treatment of childhood acute lymphoblastic leukemia.
Chronic Lymphocytic Leukemia Treatment (PDQ®)
Expert-reviewed information summary about the treatment of chronic lymphocytic leukemia.
Chronic Lymphocytic Leukemia Treatment (PDQ®)
Expert-reviewed information summary about the treatment of chronic lymphocytic leukemia.
Chronic Myelogenous Leukemia Treatment (PDQ®)
Expert-reviewed information summary about the treatment of chronic myelogenous leukemia.
Hairy Cell Leukemia Treatment (PDQ®)
Expert-reviewed information summary about the treatment of hairy cell leukemia.
x